-+ 0.00%
-+ 0.00%
-+ 0.00%
On November 14, Novartis announced that 2 of its new products and 3 new indications were successfully included in the new medical insurance drug catalogue, and 1 product was included in the commercial insurance innovative drug catalogue. The drugs included in medical insurance this time cover the treatment of various diseases such as kidney disease, hematology, and tumors, including atracentan hydrochloride tablets.
Share
Listen to the news
On November 14, Novartis announced that 2 of its new products and 3 new indications were successfully included in the new medical insurance drug catalogue, and 1 product was included in the commercial insurance innovative drug catalogue. The drugs included in medical insurance this time cover the treatment of various diseases such as kidney disease, hematology, and tumors, including atracentan hydrochloride tablets.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending